Juan Camilo Arjona Ferreira - May 28, 2021 Form 4 Insider Report for Myovant Sciences Ltd. (MYOV)

Role
Chief Medical Officer
Signature
/s/ Matthew Lang, Attorney-in-fact
Stock symbol
MYOV
Transactions as of
May 28, 2021
Transactions value $
-$63,878
Form type
4
Date filed
6/2/2021, 04:18 PM
Previous filing
May 28, 2021
Next filing
Jul 9, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYOV Common Shares Options Exercise $10.1K +1.3K +0.73% $7.78 179K May 28, 2021 Direct
transaction MYOV Common Shares Sale -$31.2K -1.3K -0.73% $24.00 178K May 28, 2021 Direct F1
transaction MYOV Common Shares Sale -$42.8K -1.78K -1% $24.00 176K May 28, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MYOV Stock Option (Right to Buy) Options Exercise $0 -1.3K -0.69% $0.00 187K May 28, 2021 Common Shares 1.3K $7.78 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a 10b5-1 trading plan.
F2 Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.
F3 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.